N	Concordance
1	(4000 mg/m2), cisplatin (50 mg/m2), and epirubicin (50 mg/m2) (VIP-E) to 107 pat
2	 samples were studied in triplicate and epirubicin concentrations were obtained 
3	wed no impairment of quality of life by epirubicin treatment. Stage D and D2max 
4	icity intervenes, or until a cumulative epirubicin dose of 1,000 mg per square 
5	a M TI  - A phase II study of high-dose epirubicin (EPI) plus cyclophosphamide  
6	      ived a combination of intravenous epirubicin hydrochloride (8 doses of 40 
7	I.   Compare the effects of 4 cycles of epirubicin followed by 4 cycles of  CMF 
8	rotective effect in  patients receiving epirubicin.[23] The risks of cardiac to
9	       an increase in the resistance to epirubicin, chlorambucil, cisplatin and 
10	 Epirubicin and Cyclophosphamide versus Epirubicin and Paclitaxel in the Treatm
11	 surgery by high-dose chemotherapy with epirubicin and cyclophosphamide  followe